Table 1

Search results17–19

Author (year)Research designLocationStudy populationResults
Jain et al17 (2022)Retrospective cohort studyIndiaA total of 167 individuals with m-CNV therapy participated in the study, resulting in the inclusion of 167 eyes. Among these, 59 eyes were treated with intravitreal ranibizumab monotherapy, while 108 eyes received bevacizumab monotherapy.The only notable factor that predicted recurrence was the number of injections administered to treat the disease in the initial episode (Cox proportional HR 2.89–3.07, 95% CI 1.28–7.45; p=0.005). Following 12 months, eyes that received a single injection during the first episode exhibited a recurrence rate of 12%, while eyes that necessitated three or more injections in the initial episode experienced a recurrence rate of 45%.
Cicinelli et al18 (2023)Retrospective cohort studyItalyThe study included a total of 310 eyes with active myopic macular neovascularisation and the median duration of follow-up was 3.5 years.Multiple recurrences were predicted by advanced age (HR=1.13 (95% CI 1.04–1.27) for every 10-year increase, p=0.006), larger size of myopic macular neovascularisation (HR=1.06 (95% CI 1.01–1.13) for every 1 mm² increase, p=0.04) and a juxtafoveal location (HR=1.88 (95% CI 1.28–2.77) compared with extrafoveal, p=0.001).
Jing et al19 (2022)Retrospective cohort studyChinaA total of 48 patients with pathologic myopia choroidal neovascularization (PM-CNV) who received conbercept treatment and underwent a period of monitoring for at least 6 months were included in the study, comprising 48 eyes in total.The binary logistic regression analysis demonstrated a significant correlation between PM-CNV recurrence and various factors, including the height of hyper-reflective foci, CNV area, as well as the presence of ellipsoid zone and retinal pigment epithelium abnormalities (p<0.05).
  • m-CNV, myopic choroidal neovascularisation; PM-CNV, pathologic myopia choroidal neovascularisation.